In Silico Characterization of Ehlers-Danlos Syndrome Causing Human Collagen Proteins
Abstract
Bioinformatic tools and computational methods have been used to analyze, characterize and to provide more detailed definition of some selected Ehlers-Danlos syndrome (EDS) causing human collagen proteins retrieved from NCBI’s Entrez Protein database. Defect in collagen causes various syndromes including Ehlers-Danlos syndrome (EDS). Here, EDS causing 11 human collagen proteins retrieved from NCBI’s Entrez Protein database are characterized by using computational methods to give detailed definition of EDS causing collagen proteins. Primary structure analysis shows that all the eleven proteins are rich in glycine (23% – 34%) and proline (17% - 23%) amino acids. The computed pI values of EDS associated collagens reveals that the proteins NP_000080.2, AAB59374.1, AAB59383.1, and AAA52041.1 are basic, the protein AAB35615.1 is strongly basic (pI>7), and the proteins NP_000081.1, NP_000079.1, NP_000384.1 and NP_056534.1 are acidic, the protein NP_000084.2 is strongly acidic (pI 79%) and the secondary structure content prediction server (SSCP) classifies all the proteins as irregular secondary structure class. The irregular structure of collagen proteins is due to the rich content of more flexible glycine and hydrophobic proline amino acids. SOSUI server identified one transmembrane region in alpha 2 type V collagen preproprotein (NP_000384.1) and classifies all the other collagens as soluble proteins. The average molecular weight of EDS causing collagen proteins calculated is…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.